Dow Jones
39.308,00 -23,90 (-0,06%) Nasdaq
18.188,30 +159,54 (+0,88%) Nikkei 225
40.913,65 +332,89 (+0,82%) EUR/USD
1,0814 +0,0027 (+0,25%) Bitcoin EUR
53.826,72 -1.928,48 (-3,46%) CMC Crypto 200
1.213,16 -48,02 (-3,81%)
PROCEPT BioRobotics Corporation (PRCT)
Dopo ore:
| Chiusura precedente | 63,16 |
| Aperto | 63,27 |
| Denaro | 0,00 x 0 |
| Domanda | 0,00 x 0 |
| Min-Max giorno | 63,03 - 64,42 |
| Intervallo di 52 settimane | 24,83 - 77,00 |
| Volume | |
| Media Volume | 621.780 |
| Capitalizzazione | 3,272B |
| Beta (mensile su 5 anni) | 1,00 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,12 |
| Prossima data utili | 25 lug 2024 - 29 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 74,00 |
GlobeNewswireThe National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT), a surgical robotics global leader, is pleased to announce that the National Institute for Health and Care Excellence (NICE) has bestowed its strongest endorsement, the "standard arrangements" recommendation, on Aquablation® therapy for the treatment of benign prostatic hyperplasia (BPH). NICE plays a pivotal role in providing guidance to enhance health and social care in the United Kingdom. For a
GlobeNewswirePROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
Main Lobby Procept BioRobotics Main Lobby Main Entrance Procept BioRobotics Main Entrance SAN JOSE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on developing transformative solutions in urology, proudly announces the grand opening of its state-of-the-art global corporate headquarters in San Jose, California. This expansive facility will accommodate the company's plans for continued growth.
- GlobeNewswire
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today the Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to investigate the safety and efficacy of Aquablation therapy for prostate cancer. The IDE approval allows PROCEPT BioRobotics to initiate a single-arm feasibility study in the United States. The data generated from
